COMMISSION IMPLEMENTING REGULATION (EU) 2019/1589
of 26 September 2019
amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances amidosulfuron, beta-cyfluthrin, bifenox, chlorotoluron, clofentezine, clomazone, cypermethrin, danozoxide, deltamethrin, dicamba, difenoconazole, diflubenzuron, diflufenican, fenoxaprop-P, fenpropidin, fludioxonil, flufenacet, fothiazate, indoxacarb, lenacil, MCPA, MCPB, nicosulfuron, picloram, prosulfocarb, pyriproxyfen, thiophanate-methyl, triflusulfuron and tritosulfuron

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Whereas:

(1) Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 (2) sets out the active substances deemed to have been approved under Regulation (EC) No 1107/2009.

(2) The approval periods of the active substances beta-cyfluthrin, chlorotoluron, clomazone, cypermethrin, danozoxide, deltamethrin, fludioxonil, flufenacet, fothiazate, indoxacarb, lenacil, MCPA, MCPB, nicosulfuron, picloram, prosulfocarb and pyriproxyfen were extended until 31 December 2019 by Implementing Regulation (EU) 2018/1796 (4).

(3) The approval period of the active substance tritosulfuron was extended until 30 November 2019 by Commission Implementing Regulation (EU) 2018/1796 (4).

(4) The approval periods of the active substances amidosulfuron, bifenox, clofentezine, dicamba, difenoconazole, diflubenzuron, diflufenican, fenoxaprop-P, fenpropidin, lenacil, nicosulfuron, picloram and pyriproxyfen were extended until 31 December 2019 by Implementing Regulation (EU) 2018/1796.

(5) The approval period of the active substance triflusulfuron will expire on 31 December 2019.

(6) Applications for the renewal of the approval of those substances were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012 (5).

(7) Due to the fact that the assessment of those substances has been delayed for reasons beyond the control of the applicants, the approvals of those active substances are likely to expire before a decision has been taken on their renewal. It is therefore necessary to extend their approval periods.

In view of the aim of the first paragraph of Article 17 of Regulation (EC) No 1107/2009, as regards cases where the Commission is to adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission is to set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later. As regards cases where the Commission is to adopt a Regulation providing for the renewal of an active substance referred to in the Annex to this Regulation, the Commission will endeavour to set, as appropriate under the circumstances, the earliest possible application date.

Implementing Regulation (EU) No 540/2011 should therefore be amended accordingly.

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 26 September 2019.

For the Commission
The President
Jean-Claude JUNCKER
ANNEX

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1) in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘31 October 2020’;

(2) in the sixth column, expiration of approval, of row 48, Beta-cyfluthrin, the date is replaced by ‘31 October 2020’;

(3) in the sixth column, expiration of approval, of row 65, Flufenacet, the date is replaced by ‘31 October 2020’;

(4) in the sixth column, expiration of approval, of row 69, Fosthiazate, the date is replaced by ‘31 October 2020’;

(5) in the sixth column, expiration of approval, of row 102, Chlorotoluron, the date is replaced by ‘31 October 2020’;

(6) in the sixth column, expiration of approval, of row 103, Cypermethrin, the date is replaced by ‘31 October 2020’;

(7) in the sixth column, expiration of approval, of row 104, Daminozide, the date is replaced by ‘31 October 2020’;

(8) in the sixth column, expiration of approval, of row 105, Thiophanate-methyl, the date is replaced by ‘31 October 2020’;

(9) in the sixth column, expiration of approval, of row 107, MCPA, the date is replaced by ‘31 October 2020’;

(10) in the sixth column, expiration of approval, of row 108, MCPB, the date is replaced by ‘31 October 2020’;

(11) in the sixth column, expiration of approval, of row 119, Indoxacarb, the date is replaced by ‘31 October 2020’;

(12) in the sixth column, expiration of approval, of row 160, Prosulfocarb, the date is replaced by ‘31 October 2020’;

(13) in the sixth column, expiration of approval, of row 161, Fludioxonil, the date is replaced by ‘31 October 2020’;

(14) in the sixth column, expiration of approval, of row 162, Clomazone, the date is replaced by ‘31 October 2020’;

(15) in the sixth column, expiration of approval, of row 169, Amidosulfuron, the date is replaced by ‘31 December 2020’;

(16) in the sixth column, expiration of approval, of row 170, Nicosulfuron, the date is replaced by ‘31 December 2020’;

(17) in the sixth column, expiration of approval, of row 171, Clofentezine, the date is replaced by ‘31 December 2020’;

(18) in the sixth column, expiration of approval, of row 172, Dicamba, the date is replaced by ‘31 December 2020’;

(19) in the sixth column, expiration of approval, of row 173, Difenconazole, the date is replaced by ‘31 December 2020’;

(20) in the sixth column, expiration of approval, of row 174, Diflubenzuron, the date is replaced by ‘31 December 2020’;

(21) in the sixth column, expiration of approval, of row 176, Lenacil, the date is replaced by ‘31 December 2020’;

(22) in the sixth column, expiration of approval, of row 178, Picloram, the date is replaced by ‘31 December 2020’;
(23) in the sixth column, expiration of approval, of row 179, Pyriproxyfen, the date is replaced by ‘31 December 2020’;
(24) in the sixth column, expiration of approval, of row 180, Bifenox, the date is replaced by ‘31 December 2020’;
(25) in the sixth column, expiration of approval, of row 181, Diflufenican, the date is replaced by ‘31 December 2020’;
(26) in the sixth column, expiration of approval, of row 182, Fenoxaprop-P, the date is replaced by ‘31 December 2020’;
(27) in the sixth column, expiration of approval, of row 183, Fenpropidin, the date is replaced by ‘31 December 2020’;
(28) in the sixth column, expiration of approval, of row 186, Tritosulfuron, the date is replaced by ‘30 November 2020’;
(29) in the sixth column, expiration of approval, of row 289, Triflusulfuron, the date is replaced by ‘31 December 2020’. 